In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC, Sarah P. Psutka, MD, MSc, reflects on her talk regarding frailty and surgical ...
In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...
The 2025 AUA Census documents significant geographic maldistribution of the urologic workforce—with 62% of US counties lacking a urologist—alongside a median practitioner age of 54 and generational ...
The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FDA is encouraging NDA holders for gels, patches, and injectables to discuss sNDAs for treating low libido in idiopathic hypogonadism, a group currently excluded from labeled indications. April 30, ...
The EMA's CHMP recommends expanding niraparib and abiraterone acetate use for mHSPC patients with BRCA1/2 mutations, based on phase 3 AMPLITUDE trial results. The AMPLITUDE trial showed significant ...
FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...
Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
The UroActive smart implant trial for male SUI has received IDE clearance from the FDA and ANSM. SOPHIA2 trial will enroll 140 male patients to assess the UroActive implant's safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results